Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2017

View Archived Issues

Cytovation raises funds to advance CyPep-1

Ultupharma divulges novel antibacterials

Sunshine Lake Pharma presents novel RNA-directed RNA polymerase inhibitors

Phase I/II data on EPI-506 presented for the treatment of mCRPC

FDA grants orphan drug designation for ALM-201 for the treatment of ovarian cancer

Celgene's CC-220 shows promise in phase II SLE study

Bayer initiates phase III ASTEROID study program of vilaprisan

Pralia approved for additional indication in Japan

Novartis files application in Japan to expand approval of Signifor

Vanucizumab trial suggests ANG-2 is not a relevant target in metastatic colorectal cancer

Swedish Orphan Biovitrum's SOBI-003 receives U.S. orphan status for MPS type III A

FDA grants glasdegib orphan designation for acute myeloid leukemia

Phase I data presented for AMG-232 in metastatic cutaneous melanoma

Novartis' Jadenu approved in Japan

Synspira raises funds to advance cystic fibrosis candidate into clinic

Angle reports topline data from Parsortix pelvic mass studies

Acer Therapeutics enters merger agreement with Opexa Therapeutics

Mitsubishi Tanabe Pharma obtains approval in Japan for Canalia combination tablets

Human neural stem cells show disease-modifying activity in Huntington's disease model

Antisense oligonucleotide QRX-411 named FDA orphan drug for retinitis pigmentosa

Spanish antitrust approval for Norgine's acquisition of Merus Labs

SOX4 found to be a poor prognostic marker in acute myeloid leukemia

Japan's MHLW approves Olumiant for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...